These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
406 related articles for article (PubMed ID: 37090741)
21. Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3. Rapoport BL; Steel HC; Benn CA; Nayler S; Smit T; Heyman L; Theron AJ; Hlatshwayo N; Kwofie LLI; Meyer PWA; Anderson R Front Oncol; 2023; 13():1097309. PubMed ID: 37064132 [TBL] [Abstract][Full Text] [Related]
22. Formation and Disordered Degradation of Neutrophil Extracellular Traps in Necrotizing Lesions of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Masuda S; Nonokawa M; Futamata E; Nishibata Y; Iwasaki S; Tsuji T; Hatanaka Y; Nakazawa D; Tanaka S; Tomaru U; Kawakami T; Atsumi T; Ishizu A Am J Pathol; 2019 Apr; 189(4):839-846. PubMed ID: 30677396 [TBL] [Abstract][Full Text] [Related]
23. Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review). Scutti JAB Int J Oncol; 2018 Apr; 52(4):1041-1056. PubMed ID: 29484440 [TBL] [Abstract][Full Text] [Related]
24. Animal models for anti-neutrophil cytoplasmic antibody-associated vasculitis: Are current models good enough? Huang F; Lv Y; Liu S; Wu H; Liu Q Animal Model Exp Med; 2023 Oct; 6(5):452-463. PubMed ID: 37614099 [TBL] [Abstract][Full Text] [Related]
25. The Features of Checkpoint Receptor-Ligand Interaction in Cancer and the Therapeutic Effectiveness of Their Inhibition. Kuzevanova A; Apanovich N; Mansorunov D; Korotaeva A; Karpukhin A Biomedicines; 2022 Aug; 10(9):. PubMed ID: 36140182 [TBL] [Abstract][Full Text] [Related]
26. Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression. Saleh R; Toor SM; Sasidharan Nair V; Elkord E Front Immunol; 2020; 11():1469. PubMed ID: 32760400 [TBL] [Abstract][Full Text] [Related]
27. Anticancer natural products targeting immune checkpoint protein network. Chun KS; Kim DH; Raut PK; Surh YJ Semin Cancer Biol; 2022 Nov; 86(Pt 3):1008-1032. PubMed ID: 34838956 [TBL] [Abstract][Full Text] [Related]
28. Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature. Yadav R; Hakobyan N; Wang JC Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569880 [TBL] [Abstract][Full Text] [Related]
30. Next generation of immune checkpoint therapy in cancer: new developments and challenges. Marin-Acevedo JA; Dholaria B; Soyano AE; Knutson KL; Chumsri S; Lou Y J Hematol Oncol; 2018 Mar; 11(1):39. PubMed ID: 29544515 [TBL] [Abstract][Full Text] [Related]
31. Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands. Kamali AN; Bautista JM; Eisenhut M; Hamedifar H Ther Adv Vaccines Immunother; 2023; 11():25151355231192043. PubMed ID: 37662491 [TBL] [Abstract][Full Text] [Related]
32. TIM-3 regulates the NETs-mediated dendritic cell activation in myeloperoxidase-ANCA-associated vasculitis. Su B; Mao X; Yin B; Chen C; Zhang M; Cui T; Hao Y Clin Exp Rheumatol; 2021; 39 Suppl 129(2):13-20. PubMed ID: 33734972 [TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma. Mei Z; Huang J; Qiao B; Lam AK Int J Oral Sci; 2020 May; 12(1):16. PubMed ID: 32461587 [TBL] [Abstract][Full Text] [Related]
34. Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach. Kgatle MM; Boshomane TMG; Lawal IO; Mokoala KMG; Mokgoro NP; Lourens N; Kairemo K; Zeevaart JR; Vorster M; Sathekge MM Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921181 [TBL] [Abstract][Full Text] [Related]
35. Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors. Catalano M; Shabani S; Venturini J; Ottanelli C; Voltolini L; Roviello G Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551630 [TBL] [Abstract][Full Text] [Related]
36. Imbalance of Circulatory T Follicular Helper and T Follicular Regulatory Cells in Patients with ANCA-Associated Vasculitis. Xu Y; Xu H; Zhen Y; Sang X; Wu H; Hu C; Ma Z; Yu M; Yi H Mediators Inflamm; 2019; 2019():8421479. PubMed ID: 31885499 [TBL] [Abstract][Full Text] [Related]
37. Reduced activated regulatory T cells and imbalance of Th17/activated Treg cells marks renal involvement in ANCA-associated vasculitis. Wang Y; Zhang S; Zhang N; Feng M; Liang Z; Zhao X; Gao C; Qin Y; Wu Y; Liu G; Zhao J; Guo H; Luo J Mol Immunol; 2020 Feb; 118():19-29. PubMed ID: 31837507 [TBL] [Abstract][Full Text] [Related]
38. Regulatory B cells in ANCA-associated vasculitis. Wilde B; Thewissen M; Damoiseaux J; Knippenberg S; Hilhorst M; van Paassen P; Witzke O; Cohen Tervaert JW Ann Rheum Dis; 2013 Aug; 72(8):1416-9. PubMed ID: 23666929 [TBL] [Abstract][Full Text] [Related]
39. PD-L1 is expressed on human activated naive effector CD4+ T cells. Regulation by dendritic cells and regulatory CD4+ T cells. Mazerolles F; Rieux-Laucat F PLoS One; 2021; 16(11):e0260206. PubMed ID: 34793567 [TBL] [Abstract][Full Text] [Related]